REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO (RGNX) will host an investor event on October 20, 2026, reviewing its surabgene lomparvovec clinical program for wet AMD.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (RGNX) will host an investor event on October 20, 2026, reviewing its surabgene lomparvovec clinical program for wet AMD. The event runs from 1:00 p.m. to 4:00 p.m. ET in New York and via webcast. Wet AMD is wet age-related macular degeneration.
Management and retina specialists will discuss the treatment landscape, unmet need, the ATMOSPHERE and ASCENT pivotal trials, and commercial readiness of surabgene lomparvovec, also called sura-vec or ABBV-RGX-314. REGENXBIO anticipates topline pivotal data in the fourth quarter of 2026. A webcast replay will remain available in the website's Investors section for approximately 30 days after the event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026
Along with a clinical program overview, the event will feature perspectives from REGENXBIO management and leading retina specialists on the treatment landscape, unmet need, ATMOSPHERE® and ASCENT® pivotal trials, and commercial readiness of sura-vec in wet AMD.
Featured key opinion leaders include:
- Gaurav Shah, M.D., FASRS, California Pacific Medical Center, Sutter Health
- Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates
- Lejla Vajzovic, M.D., FASRS, Duke University School of Medicine
- Rahul Khurana, M.D., FASRS, Northern California Retina Vitreous Associates, University of
California atSan Francisco - Ramanath Bhandari, M.D., FASRS, Springfield Clinic Eye Institute
Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives
Date: Tuesday, October 20, 2026
Time: 1:00 p.m. ET – 4:00 p.m. ET
Location:
Registration for the webcast is available at this LINK.
An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the event.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-investor-event-highlighting-surabgene-lomparvovec-sura-vec-in-wet-amd-on-october-20-302905229.html
SOURCE REGENXBIO Inc.